Proportion reporting that bleeding had stopped by treatment and time point
| Hours after infusion (N) . | FEIBA, % . | NovoSeven, % . | 90% confidence interval, %* . | P . |
|---|---|---|---|---|
| 2† (47) | 53.2 | 38.3 | 0.06-29.72 | .495 |
| 6 (46) | 76.1 | 65.2 | −2.73-24.47 | .309 |
| 12 (45) | 77.8 | 75.6 | −11.92-16.37 | .069 |
| 24 (42) | 90.5 | 85.7 | −4.75-14.28 | .038 |
| 36 (41) | 95.1 | 87.8 | −1.45-16.09 | .075 |
| 48 (41) | 95.1 | 92.7 | −4.48-9.36 | .001 |
| Hours after infusion (N) . | FEIBA, % . | NovoSeven, % . | 90% confidence interval, %* . | P . |
|---|---|---|---|---|
| 2† (47) | 53.2 | 38.3 | 0.06-29.72 | .495 |
| 6 (46) | 76.1 | 65.2 | −2.73-24.47 | .309 |
| 12 (45) | 77.8 | 75.6 | −11.92-16.37 | .069 |
| 24 (42) | 90.5 | 85.7 | −4.75-14.28 | .038 |
| 36 (41) | 95.1 | 87.8 | −1.45-16.09 | .075 |
| 48 (41) | 95.1 | 92.7 | −4.48-9.36 | .001 |
The 90% confidence interval for the difference in the proportions of patients' rating of whether the bleeding had stopped for each of the treatments (columns 2 and 3). Rejecting the null hypothesis at the .05 level is equivalent, in this setting, to showing that the upper and lower limits of the confidence interval fall within plus or minus 15%.
Prior to the second dose of NovoSeven.